Navigation Links
Ampio Strengthens Patent Protection for Lead Drug Ampion™
Date:3/20/2012

GREENWOOD VILLAGE, Colo., March 20, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion™.

Gary Connell, Ampio patent counsel from Sheridan Ross PC of Denver stated: "The allowed claims in this new patent protect pharmaceutical compositions that include the use of the low molecular weight fraction of commercially available (approved) human serum albumin for any use, including the injectable used in the osteoarthritis of the knee study conducted in Australia. The allowed patent claims further strengthen Ampio's patent portfolio by providing specific coverage for a pharmaceutical composition produced using the same method by which the Ampion™ product in clinical trials was produced."

Dr. Vaughan Clift, Chief Regulatory Officer of Ampio noted: "A meeting with the CBER (Center for Biological Evaluation and Research) division of the FDA is scheduled to occur by the end of April 2012. The purpose of the meeting is to obtain guidance and clarity about the path and conduct of pivotal trial(s) in the US for approval of Ampion™ for reducing pain in osteoarthritis of the knee. We have provided the FDA a pre-IND package that includes scientific evidence as well as the results of the osteoarthritis of the knee trial results (safety, efficacy and manufacturing data) conducted in Australia, which indicated no safety concerns and statistically significant efficacy trends c
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
2. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
3. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
4. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
5. Executive Changes at Ampio
6. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
7. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
8. Ampio Responds to Recent Publications by Anonymous Short Sellers
9. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
10. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
11. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... SIPP International Industries Inc. (OTCBB: SIPN), ... hospitality and medical technology industries announced today that they ... Japanese Consulting firm based in Osaka Japan. Upon completion ... residual revenues within three months.  FVJ ...
... Jan. 17, 2012 Bayer HealthCare today announced latest ... the Phase III CORRECT ( Co lo r ectal ... ebo after failure of standard t herapy) trial. ... improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
(Date:7/30/2014)... 2014 The family of a Vermont ... a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his ... LLP reports. According to the complaint, which was filed ... on July 25th, the decedent had been taking Xarelto ... brain bleed that ultimately led to his death on ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 Frozen ... Women are more likely to develop this nasty condition which ... and 60, and can last up to two and half ... known as frozen shoulder, and with good reason: it can ... your shirt — that is, if you aren't in too ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... a PET scan may interfere with the results seen, says ... emission tomography (PET) or computed tomography (CT) scan is done ... evaluate the effect of treatment on an already diagnosed malignant ... in the body that can be traced with the help ...
... have reportedly succeeded in generating sperm// and ovarian cells ... for Stem Cell Biology in Sheffield said that "the ... sperm and eggs to use in assisted conception treatments". ... with infertility. This research will allow embryonic stem cells ...
... processed meat can increase your chance of having colorectal ... the National Cancer Institute. ,Colon and rectum together ... cancer is also called colorectal cancer. Cancer of the ... malignant cells within the lining of colon or rectum. ...
... in schizophrenic patients with the help of seroquel ... is a chronic severe disabling mental illness. Some ... seen or heard, feelings of being persecuted, becoming ... symptomatically, but only one in five patients have ...
... Researchers had been able to find out why the diabetes ... University of Utah had found that the drug TZDs activates ... This is situated in the collecting duct of the kidney. ... in the body and causes edema. ,TZD drugs are ...
... inflammations of the gum may increase the risk of ... early in life. ,According to a research study ... Conference on Prevention of Dementia held in US, periodontal ... people. ,Alzheimer’s disease affects the brain cells and ...
Cached Medicine News:
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
Calcitonin RIA Kit...
... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: